Why Scholar Rock Holding Corporation (SRRK) Stock Fell 4.8% on Sep 18, 2026
The clearest new catalyst: Barclays downgrade and valuation reset.
Why did SRRK stock fall?
Scholar Rock shares fell 4.8% on September 18, 2026, as investors engaged in profit-taking following the company's September 11 FDA approval of Isembyld (apitegromab) for spinal muscular atrophy. The decline was reinforced by a Barclays downgrade to Equal Weight on September 15, which cited valuation concerns and noted that recent drug-approval optimism was already fully priced into the stock, despite the firm raising its price target.
- Barclays downgrade and valuation reset: Barclays downgraded Scholar Rock to Equal Weight on September 15, arguing that the market had already priced in the benefits of recent regulatory approvals and drug developments. The firm raised its price target but signaled that further upside was limited at current valuations.
- Post-approval profit-taking: Investors locked in gains following the initial rally after the September 11 FDA approval of Isembyld for spinal muscular atrophy, a key milestone that had already driven earlier enthusiasm.
Initial detection
BestStocks first flagged SRRK intraday on Sep 18, 2026; this analysis was finalized after the close using the confirmed −4.8% session move and additional catalyst research.
Show the initial intraday note
Scholar Rock shares fell 4.91% to $46.61 as investors engaged in profit-taking following the company's FDA approval of Isembyld (apitegromab) for spinal muscular atrophy on September 11, according to the web catalyst. A Barclays downgrade from Overweight to Equalweight on September 15—citing valuation concerns despite a raised $58 price target—reinforced the selling pressure. Volume was normal at 0.97x expected for this time of session.
What to watch next: Scholar Rock earnings on November 13, 2026 (date not yet confirmed), with a consensus EPS estimate of −$0.87, which will be the first opportunity to gauge early commercial uptake and guidance for Isembyld.
Frequently asked questions
Why did Scholar Rock Holding Corporation (SRRK) stock fall on Sep 18, 2026?
Scholar Rock shares fell 4.8% on September 18, 2026, as investors engaged in profit-taking following the company's September 11 FDA approval of Isembyld (apitegromab) for spinal muscular atrophy. The decline was reinforced by a Barclays downgrade to Equal Weight on September 15, which cited valuation concerns and noted that recent drug-approval optimism was already fully priced into the stock, despite the firm raising its price target.
How much did SRRK stock fall on Sep 18, 2026?
SRRK fell 4.8% during the Sep 18, 2026 trading session.
What were the main drivers behind SRRK's move?
Barclays downgrade and valuation reset; Post-approval profit-taking.